ibuzatrelvir + dabigatran etexilate

This is a **combination of ibuzatrelvir and dabigatran etexilate**. - **Dabigatran etexilate** is an oral, reversible, and direct thrombin inhibitor used primarily as an anticoagulant for prevention of stroke, systemic embolism in atrial fibrillation, and for prophylaxis or treatment of venous thromboembolism. It is a prodrug hydrolyzed to dabigatran, which directly blocks the activity of thrombin (factor IIa), thus impairing conversion of fibrinogen to fibrin and reducing blood clot formation. - **Ibuzatrelvir** is a novel oral 3CL protease inhibitor being developed as an antiviral agent, primarily for the treatment of COVID-19. Its mechanism involves inhibiting the main protease (3CLpro, also known as Mpro) of SARS-CoV-2, which is essential for viral replication. This combination would theoretically provide antiviral and anticoagulant effects, though there is no evidence such a fixed-dose combination is marketed or under clinical investigation as a combination product as of now.